Micofenolato De Mofetilo Tillomed

Mycophenolate Mofetil, the active ingredient in Micofenolato De Mofetilo Tillomed, is an antimetabolite immunosuppressant presented as an oral formulation for oral use. It is employed to prevent organ transplant rejection and to treat lupus nephritis and other autoimmune conditions in adult patients.

GNH USA supplies Micofenolato De Mofetilo Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Mycophenolate Mofetil acts on the immune system to inhibit lymphocyte proliferation, making it useful in several immunologically mediated conditions. - Prevention of organ transplant rejection: lowers the risk of acute and chronic graft rejection after kidney, heart or liver transplantation. - Treatment of lupus nephritis: reduces renal inflammation and helps preserve kidney function in systemic lupus erythematosus. - Management of certain autoimmune diseases: suppresses immune activity in disorders such as vasculitis or dermatomyositis.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Diarrhea: increased bowel movements, sometimes watery. - Headache: transient cranial discomfort. - Abdominal pain: cramping or discomfort in the stomach area. - Infections: higher susceptibility to common viral or bacterial infections.

Serious or Rare Side Effects: - Leukopenia: significant reduction in white blood cells. - Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia. - Hepatotoxicity: elevated liver enzymes or liver injury. - Malignancy risk: increased incidence of certain cancers with long‑term use. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease of the brain.

Patients should be monitored closely for safety concerns before and during therapy. - Monitor blood counts: regular CBC to detect leukopenia or anemia. - Monitor liver function: periodic LFTs to identify hepatotoxicity. - Avoid in pregnancy: drug is contraindicated; effective contraception required. - Use caution in renal impairment: dose adjustment may be needed. - Counsel on infection risk: advise prompt reporting of fever or signs of infection. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Mycophenolate Mofetil may interact with several medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Live vaccines: may cause uncontrolled infection. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): markedly reduce drug exposure. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Other immunosuppressants (e.g., azathioprine, tacrolimus): increase risk of bone marrow suppression. - ACE inhibitors or ARBs: may worsen renal function when combined. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): elevate risk of kidney injury. - Vaccines (non‑live): monitor immune response effectiveness.